IONS Q3 2021 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$133M-16.9% YoY

Gross Profit

$130M97.7% margin

Operating Income

-$86M-64.5% margin

Net Income

-$82M-62.0% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

+5.8%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$60M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$1.9B

Stockholders' Equity

$531M

Cash & Equivalents

$633M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$133M	$160M	-16.9%
Gross Profit	$130M	$157M	-17.2%
Operating Income	-$86M	-$37M	-135.0%
Net Income	-$82M	-$24M	-237.0%

Revenue Segments

Commercial

$85M39%

Spinraza Royalties

$67M31%

Research and Development Revenue Under Collaborative Agreements

$48M22%

TEGSEDI and WAYLIVRA

$16M7%

Licensing and Other Royalties

$3M1%